Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia

ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to investigate the means by which resistance to ABT-199...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kevin H., Winter, Peter S., Xie, Abigail, Roth, Cullen, Martz, Colin A., Stein, Elizabeth M., Anderson, Gray R., Tingley, Jennifer P., Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901329/
https://www.ncbi.nlm.nih.gov/pubmed/27283158
http://dx.doi.org/10.1038/srep27696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901329/
https://www.ncbi.nlm.nih.gov/pubmed/27283158
http://dx.doi.org/10.1038/srep27696

Ejemplares similares